Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
REGN Regeneron Pharmaceuticals Inc
- Stocks
- Healthcare
- NASDAQ: REGN
Price (delayed)
$498.57
Market cap
$53.83B
P/E Ratio
11.94
Dividend/share
$1.76
EPS
$41.77
Enterprise value
$53.44B
Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Tarrytown, New York. The company was founded in 1988. Originally focused on neurotrophic factors and their regenerative capabilities , it
Highlights
REGN's price to earnings (P/E) is 44% lower than its last 4 quarters average of 20.7 and 32% lower than its 5-year quarterly average of 17.1
Regeneron Pharmaceuticals's net income has increased by 17% YoY
The quick ratio has contracted by 11% YoY
Key stats
What are the main financial stats of REGN
Market
Valuations
Earnings
Shares outstanding
107.97M
Market cap
$53.83B
Enterprise value
$53.44B
Price to earnings (P/E)
11.94
Price to book (P/B)
1.85
Price to sales (P/S)
3.78
EV/EBIT
10.62
EV/EBITDA
9.67
EV/Sales
3.79
Revenue
$14.09B
Gross profit
$12.08B
Operating income
$3.83B
Net income
$4.5B
EBIT
$5.03B
EBITDA
$5.53B
Free cash flow
$3.12B
Per share
Balance sheet
Liquidity
EPS
$41.77
EPS diluted
$39.33
Free cash flow per share
$29.26
Book value per share
$268.81
Revenue per share
$132.01
TBVPS
$340.94
Total assets
$37.55B
Total liabilities
$8.16B
Debt
$2.7B
Equity
$29.39B
Working capital
$14.01B
Debt to equity
0.09
Current ratio
4.93
Quick ratio
3.9
Net debt/EBITDA
-0.07
Margins
Efficiency
Dividend
EBITDA margin
39.2%
Gross margin
85.8%
Net margin
31.9%
Operating margin
27.2%
Return on assets
12.1%
Return on equity
15.5%
Return on invested capital
15.4%
Return on capital employed
14.8%
Return on sales
35.7%
Dividend yield
0.35%
DPS
$1.76
Payout ratio
4.2%
REGN stock price
How has the Regeneron Pharmaceuticals stock price performed over time
Intraday
3.21%
1 week
1.69%
1 month
-10.73%
1 year
-50.18%
YTD
-30.01%
QTD
-21.39%
Financial performance
How have Regeneron Pharmaceuticals's revenue and profit performed over time
Revenue
$14.09B
Gross profit
$12.08B
Operating income
$3.83B
Net income
$4.5B
Gross margin
85.8%
Net margin
31.9%
Regeneron Pharmaceuticals's net income has increased by 17% YoY
The net margin has increased by 9% YoY and by 2.6% from the previous quarter
The revenue has increased by 8% YoY
Regeneron Pharmaceuticals's operating margin has decreased by 7% YoY and by 3.2% QoQ
Price vs fundamentals
How does REGN's price correlate with its fundamentals
Growth
What is Regeneron Pharmaceuticals's growth rate over time
Valuation
What is Regeneron Pharmaceuticals stock price valuation
P/E
11.94
P/B
1.85
P/S
3.78
EV/EBIT
10.62
EV/EBITDA
9.67
EV/Sales
3.79
REGN's price to earnings (P/E) is 44% lower than its last 4 quarters average of 20.7 and 32% lower than its 5-year quarterly average of 17.1
The company's EPS rose by 16% YoY and by 2.1% QoQ
REGN's price to book (P/B) is 55% less than its 5-year quarterly average of 4.0 and 45% less than its last 4 quarters average of 3.3
The equity has grown by 9% year-on-year
The P/S is 45% lower than the last 4 quarters average of 6.7 and 41% lower than the 5-year quarterly average of 6.2
The revenue has increased by 8% YoY
Efficiency
How efficient is Regeneron Pharmaceuticals business performance
The company's return on sales rose by 14% YoY and by 5% QoQ
Regeneron Pharmaceuticals's return on invested capital has increased by 7% YoY
The return on assets has increased by 2.5% year-on-year
Regeneron Pharmaceuticals's return on equity has increased by 2.6% YoY
Dividends
What is REGN's dividend history
DPS
$1.76
Dividend yield
0.35%
Payout ratio
4.2%
Recent dividends
Special dividends are included in TTM DPS and yield
Financial health
How did Regeneron Pharmaceuticals financials performed over time
Regeneron Pharmaceuticals's total liabilities has increased by 11% YoY but it has decreased by 3% QoQ
The quick ratio has contracted by 11% YoY
The debt is 91% less than the equity
REGN's debt to equity is down by 10% YoY
The equity has grown by 9% year-on-year
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.